On Thursday, U.S. President Donald Trump unveiled a deal with Eli Lilly and Novo Nordisk, two American multinational pharmaceutical companies, to lower the prices of GLP-1 weight-loss drugs, making them more affordable for all consumers. This deal not only offers price cuts to drug treatments but also expands medical coverage.
Patients covered by Medicare, a federal health insurance program, and Medicaid, a joint federal-state program, can now access the popular obesity treatment drugs, Wegovy and Zepbound, at a reduced price of $245 to $350 per month. This is a consumer discount on obesity drugs given to patients, which can be availed of from the yet-to-be-launched website “TrumpRx.Gov.” As per the latest sources, the website will go live in January 2026.
The deal announcement is one of the game-changer moves by Trump, both politically and economically. The idea is to make premium medicines more affordable in America compared to other countries.
From what we have witnessed over the years, the drug prices in the U.S. are substantially exorbitant, where patients pay thousands of dollars. But that’s over now. Thanks to Trump’s administrative efforts for building TrumpRx.Gov, a platform that allows consumers to get prescription drugs at fairer rates.
Let’s say, a weight-loss drug in another country costs $100. The U.S. would make it possible for the patient to get the same drug at a similar or better price in their home country.
Quoting Donald Trump, he says, “For many years, Americans have paid the highest prices anywhere in the world for prescription drugs much more than other countries for the exact same product. That ends today.” Starting January 2026, patients will have access to more affordable medications.
For the first time, beginning in mid-2026, Medicare will start offering coverage for obesity drugs for eligible patients. U.S. people have been waiting for this shift for a while now, and Eli Lilly & Novo Nordisk’s deals have made it possible.
Without insurance and proper discounts, patients have to shell out $1,000 a month for obesity and diabetes treatment. This deal allows more people to buy and afford drugs, and prompts insurance companies to start covering them.
Now, patients will have to pay only $50 a month for diabetes or weight loss GLP-1 treatment, either via injectable shots or oral pills. On TrumpRx.Gov, popular weight-loss drugs like Wegovy and Zepbound will cost approximately $350 a month in the initial stage, and eventually will trim to roughly $250 in the next couple of years.
Medicare patients can buy certain drugs like Ozempic, Wegovy, Mounjaro, and Zepbound at a much cheaper price of around $245 a month. Eli Lilly’s new weight-loss pill, Orforglipron, will start at $149 for the lowest dose, while its injectable Zepbound will begin at $299.
Recently, Pfizer, AstraZeneca, and EMD Serono also made deals with Trump to offer prescription drugs at lower rates for Medicaid.
Article written by: FRSC Staff
This content is solely for educational and informational purposes only. All the opinions and author’s views reflect professional expertise. Freedom Respiratory Sleep Center is not liable for outcomes based on this information. Always consult with a qualified healthcare provider for personalized medical advice. © Freedom Respiratory Sleep Center. All rights reserved.